Lu 177 Vipivotide Tetraxetan Approved for PSMA-Positive mCRPC - Targeted Oncology
6/2/2022 12:00:00 AM2 years 11 months ago
by Richard L. Wahl, MD
by Richard L. Wahl, MD
Richard L. Wahl, MD, discusses the approval of lutetium Lu 177 vipivotide tetraxetan for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.
Richard L. Wahl, MD, director of the Mallinckrodt Institute of Radiology and Elizabeth E. Mallinckrodt Professor of Radiology at Washington University School of Medicine in St. Louis, discusses the a… [+2464 chars]
full article...